Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This study is to characterize the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination
with PDR001 to adult patients with solid tumors. The study consists of a dose escalation
phase (I) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D)
for LAG525 as a single agent and in combination with PDR001, and a dose expansion phase (II)
which will characterize treatment of LAG525 as a single agent and in combination with PDR001
at the MTD or RP2D.